Početna › Burkittov limfom › Texas

Kliničke studije za Burkittov limfom u državi Texas

24 studija za Burkittov limfom traži sudionike na lokacijama u državi Texas.

Gradovi u državi Texas

Službeni tekst studije (engleski)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
i još 10

U tijeku regrutacijaFaza 2

366 Days – 46 Years · Oba spola · Ažurirano 2. lis 2026. · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Houston Methodist Hospital, Houston

U tijeku regrutacijaFaza 3

Od 18 do 39 godina · Oba spola · Ažurirano 2. lis 2026. · NCT03150693

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Texas Children's Hospital, Houston

U tijeku regrutacijaOpažajna studija

Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
i još 7

U tijeku regrutacijaFaza 2

365 Days · Oba spola · Ažurirano 25. ruj 2026. · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

The University of Texas MD Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 3

Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Baylor College Medical Center (Data Collection Only), Houston
Texas Children's Hospital (Data Collection), Houston

U tijeku regrutacijaFaza 3

Od 1 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

University of Texas MD Anderson Cancer Center ( Site 1007), Houston

U tijeku regrutacijaFaza 1/2

6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Methodist Children's Hospital, San Antonio

U tijeku regrutacijaFaza 1

Od 0 do 18 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Baylor University Medical Center, Dallas

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
i još 10

U tijeku regrutacijaFaza 2

Od 1 do 30 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
i još 12

U tijeku regrutacijaFaza 3

365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

University of Texas, Southwestern, Dallas
Baylor Texas Children's Hospital, Houston

U tijeku regrutacijaFaza 2

Od 7 do 25 godina · Oba spola · Ažurirano 19. kol 2026. · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Houston

U tijeku regrutacijaFaza 1/2

Od 12 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06137118

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

MD Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT06287229

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 2

Od 15 godina i više · Oba spola · Ažurirano 10. kol 2026. · NCT03136146

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of Texas MD Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 1/2

Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M D Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 1/2

Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT01371630

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Houston

U tijeku regrutacijaFaza 1/2

Od 12 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT07109219

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 2

Od 14 godina i više · Oba spola · Ažurirano 20. svi 2026. · NCT02877303

Study of SGR-1505 in Mature B-Cell Neoplasms

University of Texas Southwestern, Dallas

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

University of Texas MD Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 5. stu 2025. · NCT04260022

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Sarah Cannon - St. David's South Austin Medical Center, Austin
MD Anderson Cancer Center, Houston
Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio

U tijeku regrutacijaFaza 1/2

Od 15 do 50 godina · Oba spola · Ažurirano 9. ruj 2025. · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

The University of Texas M. D. Anderson Cancer Center, Houston
Methodist Healthcare System, San Antonio

U tijeku regrutacijaFaza 2

Od 1 do 25 godina · Oba spola · Ažurirano 4. svi 2025. · NCT03509961

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

MD Anderson Cancer Center, Houston

U tijeku regrutacijaFaza 1

Od 18 godina i više · Oba spola · Ažurirano 15. stu 2024. · NCT06034275

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.